Randy Schatzman, Bolt CEO (Bolt Biotherapeutics)

Bolt Bio­ther­a­peu­tics nabs $93.5M to push Provenge in­ven­tor's new idea deep­er in the clin­ic

A can­cer-fight­ing con­cept from the in­ven­tor of the first can­cer vac­cine is near­ing prime time, and its biotech de­vel­op­er has re­ceived a sig­nif­i­cant new in­fu­sion of cash to get it there.

Bolt Bio­ther­a­peu­tics an­nounced a $93.5 mil­lion Se­ries C round led by Sofinno­va In­vest­ments and joined by more than 9 oth­ers, in­clud­ing Pfiz­er Ven­tures and RA Cap­i­tal Man­age­ment. That mon­ey will go to­ward push­ing the San Fran­cis­co biotech’s plat­form of in­nate im­mune-boost­ing war­heads through its first tri­al on metasta­t­ic sol­id tu­mors and in­to sev­er­al more.

Randy Schatz­man

It’s “a fair­ly el­e­gant but sim­ple mol­e­cule,” CEO Randy Schatz­man told End­points News. “It’s ba­si­cal­ly an off-the-shelf ther­a­peu­tic that physi­cians can call on to treat their pa­tients with­out all the per­son­al­iza­tion and man­u­fac­tur­ing dif­fi­cul­ties that many of the I/O ap­proach­es have to­day.”

The ex­per­i­men­tal drug is what Bolt calls an im­mune-stim­u­lat­ing an­ti­body con­ju­gate. It’s based on a con­cept from Stan­ford im­mu­nol­o­gist Edgar En­gle­man, who in­vent­ed the first can­cer vac­cine in Provenge, a treat­ment for prostate can­cer. That vac­cine in­volves a mul­ti-step process where in­nate im­mune cells called den­drit­ic cells are ex­tract­ed, ex­posed to a pro­tein from the pa­tients’ own tu­mors (as you would ex­pose the im­mune sys­tem to a vi­ral or bac­te­r­i­al pro­tein in a tra­di­tion­al vac­cine) and then re­in­fused.

Bolt’s plat­form is de­signed to di­rect­ly ac­ti­vate den­drit­ic cells around tu­mors with­out the need for re­moval, treat­ment and re-in­fu­sion. The ther­a­py is an an­ti­body drug con­ju­gate sim­i­lar to those pro­duced by Seat­tle Ge­net­ics, ADC Ther­a­peu­tics, and Im­munomedics, each of which con­tain an an­ti­body to guide the ther­a­py like a war­head to the tu­mor. The dif­fer­ence is that in­stead of strap­ping a chem­i­cal to the an­ti­body that will kill cells in the area, Bolt’s drug has an ag­o­nist that will bind to re­cep­tors on the den­drit­ic cells and ac­ti­vate them to at­tack the tu­mor.

Edgar En­gle­man

If it works, the drug would turn the en­vi­ron­ment around the tu­mor from an im­muno-sup­pres­sive to one that could not on­ly kill the tu­mors once but pre­vent re­cur­rence. Their first can­di­date us­es a Her­ceptin biosim­i­lar to tar­get HER2, but in the­o­ry, Schatz­man said, it should work with an an­ti­body tar­get­ed at any onco­gene and Bolt is ex­plor­ing those op­tions, both in­ter­nal­ly and with part­ner­ships.

In Feb­ru­ary, five years af­ter the com­pa­ny’s foun­da­tion, they launched their first tri­al, putting the drug — known as BDC-1001 — in­to a Phase I/II tri­al for metasta­t­ic tu­mors that are HER2+, in­clud­ing gas­tric and breast can­cer. That tri­al will test the drug both as a sin­gle-agent ther­a­py and in com­bi­na­tion with Mer­ck’s Keytru­da. The idea is that ac­ti­vat­ing the im­mune sys­tem in two dif­fer­ent ways might make for a more ef­fec­tive treat­ment.

De­spite some ear­ly con­cerns, Schatz­man says, the com­pa­ny has not seen any de­lays in that tri­al from Covid-19.

Af­ter the first da­ta emerge from the Phase I/II tri­al, the com­pa­ny will move in­to tri­als specif­i­cal­ly for gas­tric and breast can­cer, look­ing to see if it can not on­ly clear can­cers ini­tial­ly but al­so, by keep­ing the im­mune sys­tem on guard, ward off re­cur­rence, an event that can come quick­ly for pa­tients with these late-stage tu­mors.

”We’re go­ing to see some quick an­swers in go­ing past what is the cur­rent stan­dard of care,” Schatz­man said. “I’d like to think it will take a long time to know where the end of this is, be­cause in that sense, we’ll have been very ef­fec­tive at treat­ing these pa­tients.”

ZS Per­spec­tive: 3 Pre­dic­tions on the Fu­ture of Cell & Gene Ther­a­pies

The field of cell and gene therapies (C&GTs) has seen a renaissance, with first generation commercial therapies such as Kymriah, Yescarta, and Luxturna laying the groundwork for an incoming wave of potentially transformative C&GTs that aim to address diverse disease areas. With this renaissance comes several potential opportunities, of which we discuss three predictions below.

Allogenic Natural Killer (NK) Cells have the potential to displace current Cell Therapies in oncology if proven durable.

Despite being early in development, Allogenic NKs are proving to be an attractive new treatment paradigm in oncology. The question of durability of response with allogenic therapies is still an unknown. Fate Therapeutics’ recent phase 1 data for FT516 showed relatively quicker relapses vs already approved autologous CAR-Ts. However, other manufacturers, like Allogene for their allogenic CAR-T therapy ALLO-501A, are exploring novel lymphodepletion approaches to improve persistence of allogenic cells. Nevertheless, allogenic NKs demonstrate a strong value proposition relative to their T cell counterparts due to comparable response rates (so far) combined with the added advantage of a significantly safer AE profile. Specifically, little to no risk of graft versus host disease (GvHD), cytotoxic release syndrome (CRS), and neurotoxicity (NT) have been seen so far with allogenic NK cells (Fig. 1). In addition, being able to harness an allogenic cell source gives way to operational advantages as “off-the-shelf” products provide improved turnaround time (TAT), scalability, and potentially reduced cost. NKs are currently in development for a variety of overlapping hematological indications with chimeric antigen receptor T cells (CAR-Ts) today, and the question remains to what extent they will disrupt the current cell therapy landscape. Click for more details.

Susan Galbraith, AstraZeneca EVP, Oncology R&D

Can­cer pow­er­house As­traZeneca rolls the dice on a $75M cash bet on a buzzy up­start in the on­col­o­gy field

After establishing itself in the front ranks of cancer drug developers and marketers, AstraZeneca is putting its scientific shoulder — and a significant amount of cash — behind the wheel of a brash new upstart in the biotech world.

The pharma giant trumpeted news this morning that it is handing over $75 million upfront to ally itself with Scorpion Therapeutics, one of those biotechs that was newly birthed by some top scientific, venture and executive talent and bequeathed with a fortune by way of a bankroll to advance an only hazily explained drug platform. And they are still very much in the discovery and preclinical phase.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

Lat­est news on Pfiz­er's $3B+ JAK1 win; Pacts over M&A at #JPM22; 2021 by the num­bers; Bio­gen's Aduhelm reck­on­ing; The sto­ry of sotro­vimab; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

For those of you who attended #JPM22 in any shape or form, we hope you had a fruitful time. Regardless of how you spent the past hectic week, may your weekend be just what you need it to be.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

A $3B+ peak sales win? Pfiz­er thinks so, as FDA of­fers a tardy green light to its JAK1 drug abroc­i­tinib

Back in the fall of 2020, newly crowned Pfizer chief Albert Bourla confidently put their JAK1 inhibitor abrocitinib at the top of the list of blockbuster drugs in the late-stage pipeline with a $3 billion-plus peak sales estimate.

Since then it’s been subjected to serious criticism for the safety warnings associated with the class, held back by a cautious FDA and questioned when researchers rolled out a top-line boast that their heavyweight contender had beaten the champ in the field of atopic dermatitis — Dupixent — in a head-to-head study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

Robert Califf, FDA commissioner nominee (Graeme Sloan/Sipa USA/Sipa via AP Images)

Rob Califf ad­vances as Biden's FDA nom­i­nee, with a close com­mit­tee vote

Rob Califf’s second confirmation process as FDA commissioner is already much more difficult than his near unanimous confirmation under the Obama administration.

The Senate Health Committee on Thursday voted 13-8 in favor of advancing Califf’s nomination to a full Senate vote. Several Democrats voted against Califf, including Sen. Bernie Sanders and Sen. Maggie Hassan. Several other Democrats who aren’t on the committee, like West Virginia’s Joe Manchin and Ed Markey of Massachusetts, also said Thursday that they would not vote for Califf. Markey, Hassan and Manchin all previously expressed reservations about the prospect of Janet Woodcock as an FDA commissioner nominee too.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

Michel Vounatsos, Biogen CEO (World Economic Forum/Ciaran McCrickard)

Bio­gen vows to fight CM­S' draft cov­er­age de­ci­sion for Aduhelm be­fore April fi­nal­iza­tion

Biogen executives made clear in an investor call Thursday they are not preparing to run a new CMS-approved clinical trial for their controversial Alzheimer’s drug anytime soon.

As requested in a draft national coverage decision from CMS earlier this week, Biogen and other anti-amyloid drugs will need to show “a meaningful improvement in health outcomes” for Alzheimer’s patients in a randomized, placebo-controlled trial to get paid for their drugs, rather than just the reduction in amyloid plaques that won Aduhelm its accelerated approval in June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.

CRO own­er pleads guilty to ob­struct­ing FDA in­ves­ti­ga­tion in­to fal­si­fied clin­i­cal tri­al da­ta

The co-owner of a Florida-based clinical research site pleaded guilty to lying to an FDA investigator during a 2017 inspection, revealing that she falsely portrayed part of a GlaxoSmithKline pediatric asthma study as legitimate, when in fact she knew that certain data had been falsified, the Department of Justice said Wednesday.

Three other employees — Yvelice Villaman Bencosme, Lisett Raventos and Maytee Lledo — previously pleaded guilty and were sentenced in connection with falsifying data associated with the trial at the CRO Unlimited Medical Research.

‘Skin­ny la­bels’ on gener­ics can save pa­tients mon­ey, re­search shows, but re­cent court de­ci­sions cloud fu­ture

New research shows how generic drug companies can successfully market a limited number of approved indications for a brand name drug, prior to coming to market for all of the indications. But several recent court decisions have created a layer of uncertainty around these so-called “skinny” labels.

While courts have generally allowed generic manufacturers to use their statutorily permitted skinny-label approvals, last summer, a federal circuit court found that Teva Pharmaceuticals was liable for inducing prescribers and patients to infringe GlaxoSmithKline’s patents through advertising and marketing practices that suggested Teva’s generic, with its skinny label, could be employed for the patented uses.

A patient in Alaska receiving an antibody infusion to prevent Covid hospitalizations in September. All but one of these treatments has been rendered useless by Omicron (Rick Bowmer/AP Images)

How a tiny Swiss lab and two old blood sam­ples cre­at­ed one of the on­ly ef­fec­tive drugs against Omi­cron (and why we have so lit­tle of it)

Exactly a decade before a novel coronavirus broke out in Wuhan, Davide Corti — a newly-minted immunologist with frameless glasses and a quick laugh — walked into a cramped lab on the top floor of an office building two hours outside Zurich. He had only enough money for two technicians and the ceiling was so low in parts that short stature was a job requirement, but Corti believed it’d be enough to test an idea he thought could change medicine.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.